Active ingredientTirzepatideCat. No. P-T135-001CAS 2023788-19-2Family · Pharmaceutical analytical standards
Tirzepatide
A peptide that activates the receptors of two gut hormones, GIP and GLP-1, together, regarded by the FDA as first in its class. Approved for type 2 diabetes in the United States in May 2022 and in the European Union in September 2022; in the United States also for obstructive sleep apnoea since 2024. This family brings together the active ingredient and other impurities.
Did you know?It is a 39-amino-acid peptide modelled on the human hormone GIP, with a 20-carbon fatty acid chain that binds it to blood albumin and prolongs its action.
Go to the active ingredient →Active ingredientTirzepatideCat. No. P-T135-001CAS 2023788-19-2
ImpurityD-Gln19-Tirzepatide (Sodium Salt)Cat. No. P-T135-004
ImpurityD-Gln24-Tirzepatide (Sodium Salt)Cat. No. P-T135-005
ImpurityD-Leu26-Tirzepatide (Sodium Salt)Cat. No. P-T135-008
ImpurityD-Ser11-Tirzepatide (Sodium Salt)Cat. No. P-T135-009
ImpurityD-Ser8-Tirzepatide (Sodium Salt)Cat. No. P-T135-010No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.